| 摘要 |
PROBLEM TO BE SOLVED: To provide a biocompatible polymer-conjugated functional FVIII polypeptide having improved pharmacokinetic characteristics and therapeutic characteristics, having reduced binding to inhibitory antibodies against the related protein, possessing greater duration of action in vivo, and is a homogeneous product and product material, and to provide a pharmaceutical composition thereof.SOLUTION: The invention provides a pharmaceutical composition which comprises a conjugate having a factor VIII procoagulant activity comprising a functional factor VIII polypeptide which is covalently attached to one or more biocompatible polymers at one or more predefined sites on the polypeptide, and a pharmaceutically acceptable additive. In the conjugate, the biocompatible polymer contains polyethylene glycol comprising a methoxy polyethylene glycol. The pharmaceutical composition is used for the treatment of hemophilia A. |
